Retina-Vitreous
2011 , Vol 19 , Num 2
Factors Affecting the Final Visual Acuity and Anatomical Success in Intravitreal Ranibizumab Applications in Age-Related Macular Degeneration
1S.B. Ankara Eğitim ve Araştırma Hastanesi, 1. Göz Kliniği, Ankara, Doç. Dr.2S.B. Ankara Eğitim ve Araştırma Hastanesi, 1. Göz Kliniği, Ankara, Uzm. Dr.
3S.B. Ankara Eğitim ve Araştırma Hastanesi, 2. Göz Kliniği, Ankara, Doç. Dr.
4S.B. Ankara Eğitim ve Araştırma Hastanesi, 1. Göz Kliniği, Ankara, Asist. Dr.
5S.B. Ankara Eğitim ve Araştırma Hastanesi, 2. Göz Kliniği, Ankara, Uzm. Dr. Purpose: To evaluate the factors affecting the last functional success in ranibizumab injected cases in the treatment of choroidal neovascularization (CNV) due to age-related macular degeneration.
Materials and Methods: Sixty-five eyes of 62 patients that were injected with ranibizumab for the treatment of CNV secondary to age-related macular degeneration in our clinic were examined retrospectively between January 2008 and March 2010. Visual acuity (VA) with ETDRS chart, and optical coherence thomography (OCT) and florescein angiography (FA) findings were evaluated before the treatment. Intravitreal ranibizumab injections after a standard 3 dose injection were repeated according to vision and OCT findings.
Results: Thirty-four (54.8%) patients were female and 28 (45.2%) were male. Mean age was 70.8±8.7 (50-85), and the mean follow-up period was 8.2±3.7 (6-25) months. Mean injection number was 3.39±1.24 (2-10). While VA before the treatment was 47.03±21.18 letters, it was 56.15±22.86 letters after treatment. The age of patients, sex, and location of CNV were found to have no significant effect on the last VA, and response of the classic CNV to treatment was found to be beter than the occult ones (p<0.001). Patients with a starting VA under 35 letters had the highest increase in VA (p<0.001).
Conclusion: Visual gain in patients with a lower starting VA was found to be higher when ranibizumab was applied in the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration. Keywords : Age-related macular degeneration, ranibizumab, visual acuity
